Device Trial Radar · NCT04325464
A Remote, 9-week Insomnia Treatment Trial to Collect Real World Data for a Digital Therapeutic
Last checked: Nov 20, 2026Latest source record: Feb 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,590
Actual
Start
Feb 18, 2020
Primary completion
Oct 21, 2022
Study completion Oct 31, 2024
Sponsor
- Lead sponsor
- Pear Therapeutics, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Mar 27, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to collect data in a real-world environment, for a digital therapeutic that delivers CBT-I through a decentralized clinical trial, open to participants with chronic insomnia.
Conditions
- Chronic Insomnia
Interventions
PEAR-003ADevice
PEAR-003A delivers CBT-I through a decentralized clinical trial open to participants with chronic insomnia
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Insomnia Severity Index (ISI)Time frame: From Baseline to Day 63 (End of Treatment) and Days 243, 428, 610, 793 (Follow-up)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pear Therapeutics, Inc.
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.